and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination should be administered to all RMD patients taking immunosuppressive medication; 2) recombinant zoster vaccination is recommended for RMD patients >18 years of age taking immunosuppressive medication; 3) methotrexate should be held for 2 weeks after influenza vaccination if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology. org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines Voting Panel consensus required